Fredrik Schjesvold, MD, PhD, discusses a phase 1 trial of a trispecific drug designed to boost T-cell activation in myeloma and lymphoma treatment. While the…
At the free, LIVE class, you’ll get everything you need to make your decision & upgrade your job in 2025, regardless if you stay or…
Trust in U.S. health care is declining due to systemic issues, including economic strains, fraud, and leadership failures, but approaches like value-based care, patient engagement,…
A blog about biases in the conduct, interpretation, and application of evidence from clinical trials in medicine
Our results suggest that [89Zr]Zr-girentuximab PET–CT has a favourable safety profile and is a highly accurate, non-invasive imaging modality for the detection and characterisation of…
Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive…
Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in clear-cell renal-cell carcinoma in early-phase studies. In a phase 3, multicenter, open-label, active-controlled tri…
Belzutifan is a first-in-class hypoxia-inducible factor subunit 2α (HIF-2α) inhibitor approved at a dose of 120 mg once daily for certain adults with VHL disease…
The new price cap, part of the Inflation Reduction Act, will apply to all prescription drugs covered by Medicare.
From AI to optogenetics, new techniques and strategies are enabling researchers to learn from cognitive disorders and probe the root of consciousness
